SCHEMBL6569749

SCHEMBL6569749

O=C(NN=Cc1cc(Cl)cc(Cl)c1O)c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.63
MEN1 O00255 4/20 0.63
KDM4E B2RXH2 4/20 0.63
NPC1 O15118 3/20 0.63
TDP1 Q9NUW8 3/20 0.63
USP2 O75604 1/20 0.63
MCOLN3 Q8TDD5 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
PIK3CG P48736 1/20 0.54
SIRT1 Q96EB6 3/20 0.50
RAB9A P51151 3/20 0.50
MAPT P10636 3/20 0.50
PKM P14618 1/20 0.50
ATM Q13315 1/20 0.50
PSMD14 O00487 3/20 0.49
MMP2 P08253 2/20 0.49
KDM1A O60341 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6569745 1.00 KMT2A (0.63) KMT2AMEN1KDM4ENPC1TDP1
SCHEMBL684865 0.87 KDM4E (0.74) KMT2AMEN1KDM4ENPC1TDP1
SCHEMBL6751406 0.84 MAPT (0.58) KMT2AMEN1NPC1L3MBTL1RAB9A
SCHEMBL6751404 0.84 MAPT (0.58) KMT2AMEN1NPC1L3MBTL1RAB9A
SCHEMBL683833 0.83 KDM4E (0.67) KMT2AMEN1KDM4ENPC1TDP1
SCHEMBL684848 0.83 NPC1 (0.75) KMT2AMEN1KDM4ENPC1TDP1
SCHEMBL684862 0.83 KDM4E (0.79) KMT2AMEN1KDM4ENPC1TDP1
SCHEMBL20587615 0.82 MEN1 (0.67) KMT2AMEN1KDM4ENPC1TDP1
SCHEMBL20587616 0.82 MEN1 (0.67) KMT2AMEN1KDM4ENPC1TDP1
SCHEMBL22179624 0.82 MEN1 (0.67) KMT2AMEN1KDM4ENPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KMT2A 3368/4885MEN1 2514/4885KDM4E 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.